Table 1.
Pharmacoepidemiologic studies.
| Reference | CGRP-mAb | Patients (n) | Women (%) | Mean Age (Years) | Migraine Diagnosis Available/Diagnosis According to | Inclusion of Patients with | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Migraine with Aura | Chronic Migraine | Medication Overuse | Prior Treatment Failure | Other Prophylactic Medication | ||||||
| [32] | E | 82 | 85.4 | 45 | Yes/ICD-10 | NA | NA | NA | Yes | Yes |
| [33] | E | 4437 | 85.8 | 47 | Yes/ICD-10 | Yes | Yes | NA | NA | Yes |
| [34] | E | 14,282 | 83.0 | 46 | No | Yes | Yes | NA | Yes | NA |
| [35] | E | 29,451 | 79.2 | 47 | No | NA | NA | NA | Yes | Yes |
| [36] | F | 172 | 83.7 | 46 | No | NA | NA | NA | Yes | Yes |
| [37] | E, OBTA | 2676 | 91.6 | 50 | Yes/ICD | Yes | Yes | NA | Yes | Yes |
| [38] | E | 3171 | 84.8 | 51 | Yes/ICD | Yes | Yes | NA | Yes | Yes |
| [39] | E, F, G | 3082 | 85.7 | 44 | Yes/ICD-10 | Yes | Yes | NA | Yes | Yes |
Abbreviations: E erenumab, F fremanezumab, G galcanezumab, OBTA OnabotulinumtoxinA, ICD International Classification of Diseases, ICD-10 International Classification of Diseases, Tenth Revision, NA: information not available.